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Abstract
We produced recombinant human thrombin mutants to investigate the correlation between the thrombin enzyme and
mitogenic activity. Single amino acid substitutions were introduced in the catalytic triad (H43N, D99N, S205A, S205T), in
the oxy-anion binding site (G203A) and in the anion binding exosite-1 region (R73E). Proteins were produced as
prethrombin-2 mutants secreted in the culture medium of DXB11-derived cell lines. All mutants were activated by ecarin to
the corresponding thrombin mutants; the enzymatic activity was assayed on a chromogenic substrate and on the
procoagulant substrate fibrinogen. Mutations S205A and G203A completely abolished the enzyme activity. Mutations
H43N, D99N and S205T dramatically impaired the enzyme activity toward both substrates. The R73E mutation dissociated
the amidolytic activity and the clotting activity of the protein. The ability of thrombin mutants to induce proliferation was
investigated in NIH3T3 mouse fibroblasts and rat cortical astrocytes. The ability of the thrombin mutants to revert astrocyte
stellation was also studied. The mitogenic activity and the effect on the astrocyte stellation of the thrombin mutants
correlated with their enzymatic activity. Furthermore the receptor occupancy by the inactive S205A mutant prevented the
thrombin effects providing strong evidence that a proteolytically activated receptor is involved in cellular responses to
thrombin. ß 1999 Elsevier Science B.V. All rights reserved.
Keywords: Thrombin mutant; Thrombin receptor; Astrocyte stellation; Cell proliferation; Protease-activated receptor expression;
Methotrexate resistant cell
1. Introduction
Thrombin (EC 3.4.21.5) is a peculiar serine pro-
tease that interacts with a large number of substrates,
proteins and cell surface receptors. In fact, besides its
involvement in hemostasis control [1], thrombin
0167-4889 / 99 / $ ^ see front matter ß 1999 Elsevier Science B.V. All rights reserved.
PII: S 0 1 6 7 - 4 8 8 9 ( 9 9 ) 0 0 0 8 6 - 5
* Corresponding author. Fax: +39-81-746-3074;
E-mail : pietropaolo@dbbm.unina.it
1 Present address: Istituto di Farmacologia, Facolta' di Medici-
na e Chirurgia, Universita' di Genova, and Servizio di Farmaco-
logia, IST, Istituto Nazionale Ricerca sul Cancro, Largo Rosan-
na Benzi 10, Genova, I-16132 Italy.
BBAMCR 14513 30-7-99
Biochimica et Biophysica Acta 1451 (1999) 173^186
www.elsevier.com/locate/bba
plays an important role in the regulation of other
physiological processes. In vitro, thrombin is chemo-
tactic and mitogenic for human peripheral blood
monocytes, and for various macrophage cell lines
[2] ; it is also mitogenic for ¢broblasts [3] and astro-
cytes [4]. These cellular properties implicated throm-
bin in tissue repair and wound healing [5]. In addi-
tion, the ability to inhibit neurite outgrowth [6] and
to revert astrocyte stellation [4] suggests a role for
thrombin in neuronal and astroglial di¡erentiation,
and a thrombin/inhibitor imbalance could be in-
volved in Alzheimer disease [7].
Thrombin enzymatic activity is essential for the
cleavage of procoagulant substrates, such as ¢brino-
gen, for the activation of coagulation factors and for
the induction of platelet aggregation. In the anti-co-
agulant pathway, protein C activation also requires a
proteolytically active thrombin. In fact, functional
analysis has revealed the loss of hemostatic functions
of a thrombin molecule carrying a S205A mutation
[8,9].
Cloning of a platelet receptor for thrombin re-
vealed a novel proteolytic mechanism of activation:
a thrombin-mediated cleavage occurs in the N-termi-
nal moiety of the receptor thus unmasking a new N-
terminus which is able to trigger signal transduction
[10]. However, the mechanism by which thrombin
exerts cellular properties is far from clear. Moreover,
whether or not the proteolytic activation of a recep-
tor is responsible for chemotactic and mitogenic re-
sponses has been long debated. In 1978, Carney et al.
[11] demonstrated that the proliferative events in-
duced by K-thrombin required full enzymatic activ-
ity. Subsequently, Bar-Shavit et al. [2] showed that
enzymatically inactive diisopropyl £uorophosphate
(DFP)-conjugated K-thrombin is chemotactic and
mitogenic for the murine macrophage cell line J774
but has no mitogenic e¡ect on Chinese hamster lung
¢broblasts (CHL). Thus, the authors postulated a
hormone-like non proteolytic mechanism for murine
macrophage cell line J774. In contrast, Joseph and
MacDermot [12] reported that catalytically inactive
TLCK-thrombin does not induce proliferation in the
human leukemic monocyte/macrophage cell line
U937. Finally, studies by di¡erent authors [13,14]
demonstrated that the active site mutant S205A,
although devoid of enzymatic activity, is able to elicit
a chemotactic response in human neutrophils [14]
and monocytes [13]. It has been reported that throm-
bin enzymatic activity is also required to induce pro-
liferation of astrocytes [4,15] and to modulate mor-
phological di¡erentiation of astrocytes and neuronal
cells [16,17], since these cells respond to a receptor
agonist peptide [4] and to protease-nexin-1 inhibition
of thrombin e¡ects [15]. Thrombin mutants produced
by genetic engineering of prothrombin cDNA repre-
sent an appropriate tool to unequivocally and di-
rectly de¢ne the role of catalytic activity in cellular
activities of thrombin and also to study the involve-
ment of a single domain and speci¢c residues in such
activities. To this aim, we designed and produced
recombinant thrombin mutants with altered enzy-
matic activity, and we performed the analysis of their
mitogenic activity on mouse ¢broblasts and rat cort-
ical astrocytes and the analysis of their ability to
revert stellation of rat astrocytes. We demonstrate a
correlation between the enzyme activity of thrombin
and its activity as a mitogen and as a modulator of
morphological di¡erentiation. This ¢nding is com-
patible with a mechanism of proteolytic activation
of a thrombin receptor that is involved in the pro-
liferation of both NIH3T3 ¢broblasts and rat astro-
cytes. In addition, we demonstrate that proteolytic
activation of a receptor is involved also in the rever-
sion of stellation of rat cortical astrocytes.
2. Materials and methods
2.1. Materials
Human K-thrombin (1000 NIH units/mg of pro-
tein), ecarin from Echis carinatus snake venom, chro-
mogenic substrate D-Phe-L-pipecolyl-L-Arg-p-nitro-
anilide triacetate salt (S-2238), human plasma
¢brinogen were from Sigma-Aldrich (Italy). Poly-
clonal anti-human prothrombin rabbit antibodies
were from Nordic Immunological Laboratories
(The Netherlands); 2.2P-azino-di-(3-ethyl-benzothia-
zolinsulfonate) (ABTS) was obtained from Boehr-
inger Mannheim (FRG). Anti-human PPACK-K-
thrombin IgGs were raised in rabbits, the IgG frac-
tion of the antiserum was puri¢ed on a proteinA^
Sepharose column (Pharmacia, Sweden). An aliquot
of this IgG fraction was biotinylated and used in the
ELISA, as described previously [18]. Hexa-random
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primers and dNTPs were purchased from Pharmacia
(Sweden). Oligonucleotides were obtained from
Ceinge-Advanced Biotechnologies (Italy). Moloney
murine leukemia virus (Moloney-MLV) reverse tran-
scriptase was from MBI Fermentas (Lithuania). Am-
pliTaq-Gold was from Perkin-Elmer (USA).
2.2. Cell cultures and DNA transfections
NIH3T3 mouse ¢broblasts (ATCC CRL 1658)
were cultured in Dulbecco’s minimal essential me-
dium (DMEM) supplemented with 10% fetal calf se-
rum (FCS); the Chinese hamster ovary cells (CHO),
mutant clone DXB11 [19], were grown in K-medium
supplemented with 10% FCS. All culture media were
also supplemented with 1.5 mM L-glutamine, penicil-
lin (50 IU/ml) and streptomycin 50 Wg/ml. The cells
were maintained at 37‡C in a 5% CO2 atmosphere
and were subcultured twice a week by 5^8-fold dilu-
tion with culture medium.
Primary cultures of rat cortical type-1 astrocytes
were obtained as described by McCarthy and DeVel-
lis [20] with modi¢cations [21]. Brie£y, 2^3-day-old
Wistar rats (Charles River, Trieste, Italy) were de-
capitated; the brains were removed under aseptic
conditions and placed in phosphate-bu¡ered saline
(PBS; ICN-Biomedical, Milan, Italy) containing
100 IU/ml of penicillin and 100 Wg/ml of streptomy-
cin (P/S). Under a stereomicroscope, the meninges
were removed and the cerebral cortex was dissected.
The tissue was cut into small fragments, exposed to
trypsin (0.125% in PBS) for 20 min at 37‡C, and
mechanically dissociated in DMEM containing P/S,
10% FCS (HyClone, The Netherlands) and 2 mM
glutamine (ICN) to obtain single cells. Under these
conditions, cell viability was greater than 90%. The
medium was changed after 24 h and then twice a
week. The cultures were vigorously shaken to remove
non-adherent cells. The cells were subcultured twice
before starting the experiments. This protocol pro-
duced cultures with s 95% glial ¢brillary acidic pro-
tein-positive (GFAP) cells [22].
The calcium phosphate precipitation technique [23]
was used for DNA transfections. Cells were trans-
fected with 20 Wg of plasmid DNA in 100-mm
dishes; after 15 h, precipitates were washed o¡ and
fresh medium was added to the cells.
2.3. Construction of s-prethrombin-2 mutants
Single point mutations in the B-chain of the hu-
man K-thrombin were obtained by oligonucleotide
directed-mutagenesis [24]. Amino acid substitutions
were introduced in positions H43(57), R73(77A),
D99(102), G203(193), D204(194) and S205(195)
(numbering begins from the ¢rst residue of the
thrombin B-chain; the chymotrypsinogen numbering
is in parentheses) using as a template a cDNA coding
for a secreted form of human prethrombin-2 (s-pre-
thrombin-2) [18]. Two experimental approaches were
used: (a) cloning of the cDNA coding for human s-
prethrombin-2 in the single strand phage M13 [25]
followed by site-directed mutagenesis; and (b) po-
lymerase chain reaction (PCR) [26] on pDEX-sThr
vector [18]. Synthetic oligonucleotides carrying the
appropriate codon mutation were used as primers
for the single strand DNA elongation and for PCR
reactions.
All mutated cDNAs were sequenced [27] in their
entirety to ascertain that no base changes were intro-
duced during the mutagenesis procedures. RNA and
protein analysis were performed as described [18].
2.4. Production of s-prethrombin-2 mutants:
puri¢cation, ecarin activation and quantitation
of the recombinant proteins
Transfection experiments were performed using a
dihydrofolate reductase (DHFR)-de¢cient strain,
DXB11, derived from the CHO cell line [19], ob-
tained from Dr. L. Chasin (Columbia University,
New York, NY, USA). The stable transfectants
were selected as described by Russo et al. [18].
Brie£y, after transfection, dhfr cells were selected
using K-medium lacking thymidine and hypoxan-
thine, supplemented with dialyzed FCS. To increase
the production of the recombinant proteins, gene
ampli¢cation was induced by exposing cells to in-
creasing concentrations (up to 40 nM) of methotrex-
ate (MTX), a DHFR inhibitor. Several stable trans-
formants were selected for each thrombin mutant.
Culture media were assayed for production of re-
combinant proteins by Western-blot and the clones
with a higher level of protein secretion were chosen
for further characterization and protein production.
Cells were grown in 150-mm plates and, when they
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reached semicon£uence, culture medium was substi-
tuted with 20 ml of serum-free medium. After 48 h,
medium was collected, centrifuged at 6000Ug for
20 min to remove cells and debris. Culture media
were concentrated by a chromatographic step on a
heparin^Sepharose CL-6B (Pharmacia Biotech AB)
column. Medium was then loaded on a 1-ml column
previously equilibrated with 25 mM Na2HPO4-
NaH2PO4, pH 7.2 (Na-Pi bu¡er). After sample load-
ing, the column was washed exhaustively using
30 vols. of Na-Pi bu¡er to remove unbound proteins.
Finally, proteins were eluted with a 10-vol. step gra-
dient 0^1 M NaCl in Na-Pi bu¡er. Fractions of 1 ml
were collected; void volume and eluted fractions
were monitored for proteins by a Bio-Rad assay
(Bio-Rad, FRG) at 595 nm and proteins were ana-
lyzed by SDS-PAGE and immunoblotting in reduc-
ing and non-reducing conditions. Fractions contain-
ing thrombin mutants were pooled and in vitro
activated with ecarin from E. carinatus venom. Acti-
vation was as described by Owen et al. [28]; ecarin
was used at an enzyme/substrate ratio of 1:40 (w/w)
in a bu¡er containing 50 mM Tris-HCl pH 8.0, 0.1 M
NaCl and 0.1% PEG 6000 and with a ¢nal concen-
tration of 100 Wg/ml mutant protein (2.7 WM), at
37‡C for 1 h. The reaction was stopped by the addi-
tion of EDTA to yield a ¢nal concentration of 1 mM.
The activation was con¢rmed by SDS-PAGE, and
amidolytic assay for the enzymatically active mutants
(results not shown). Samples were concentrated by a
Centriprep-10 concentrator (Amicon, Grace Com-
pany, USA) and subsequently desalted on a pre-
packed PD-10 Sephadex G-25 M column (Pharmacia
Biotech). Following elution with Na-Pi bu¡er, sam-
ples were subjected to a further chromatographic
step on the heparin^Sepharose CL-6B column, using
the experimental conditions described above. The pu-
rity and the activation were con¢rmed by silver stain-
ing, Western blotting and chromogenic substrate as-
say (results not shown). Fractions containing
activated mutant proteins were pooled and the
thrombin concentration was measured by ELISA
[18], using as a standard K-thrombin puri¢ed from
human plasma, and by measuring the optical density
at 280 nm, using an extinction coe⁄cient (1 mg/ml)
of 1.38 [29]. Puri¢ed thrombin mutants were ali-
quoted and remained stable at 380‡C for several
months.
2.5. Amidolytic assay and ¢brinogen clotting assay
The amidolytic activity of thrombin mutants was
measured by a chromogenic substrate assay, using
the synthetic peptide S-2238 as substrate. The assay
was performed in polystyrene cuvettes at 25‡C in 50
mM Tris-HCl pH 8.0, 0.1 M NaCl and 0.1% PEG
6000; 200 Wl of activated recombinant thrombin
(r-thrombin) or mutants thereof (¢nal concentration
2 nM for r-thrombin and R73E, and 0.5 WM for
H43N, D99N, S205T, G203A and S205A) were
added to 800 Wl S-2238 (¢nal concentration 1.25,
2.5, 5.0, 7.5, and 10 WM). The velocity of the reaction
was monitored at 405 nm at 30-s intervals for 10 min,
unless otherwise indicated. The amount of product
was calculated using an extinction coe⁄cient of 9920
M31 cm31 for p-nitroaniline at 405 nm [30]. Km
values were determined by Eadie^Hofstee plots [31]
and kcat values were calculated using the formula
kcat = Vmax/concentration of protein.
The coagulant activity of thrombin mutants was
determined by a ¢brinogen clotting assay. The ex-
periments were carried out in a 96-well microtiter
plate, at 25‡C, and the samples, containing r-throm-
bin or thrombin mutants at a protein concentra-
tion showing comparable amidolytic activity, were
incubated in 50 Wl of 50 mM Tris, 100 mM NaCl,
0.1% PEG 6000, pH 7.8. The reaction was initiated
by adding 200 Wl of human ¢brinogen (Sigma) at a
concentration of 2 mg/ml and the velocity was fol-
lowed at 405 nm at 30-s intervals for 40 min with a
microtiter plate reader (TitertekPlus, ICN Flow,
UK).
2.6. Cell proliferation assays
Cell proliferation assays were performed on the
mouse ¢broblast NIH3T3 cell line and on primary
cultures of rat cortical type-1 astrocytes. Cells were
seeded at a density of 1.2U104 cells/cm2 in a 24-well
plate in a ¢nal volume of 0.5 ml. To obtain growth-
arrested cells, serum was removed from the culture
medium for 48 h (NIH3T3) or 24 h (astrocytes).
Quiescent cells were then exposed for 48 h
(NIH3T3) or 24 h (astrocytes) to increasing concen-
trations of puri¢ed thrombin mutants. DNA syn-
thesis was evaluated by means of the [3H]thymidine
incorporation. Two microcuries/ml [3H]thymidine
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(Amersham, UK) were added to the wells. Four
hours after labeling, cells were washed with PBS
lacking Ca2 and Mg2, exposed to trypsin and
then harvested on a glass ¢ber ¢lter (Glass micro¢ber
¢lters GF/A, Whatman, UK). [3H]Thymidine incor-
poration was determined by monitoring trichloroace-
tic acid precipitation, as reported [32]. Liquid scintil-
lation counting was used and the results were
expressed as a percent of basal value.
2.7. Stellation assay
Puri¢ed astrocytes were plated at a density of
3U104 cells/cm2 in 24-well dishes and cultured for
24 h in DMEM supplemented with 10% FCS. Cells
were then di¡erentiated to a stellate morphology by
treatment with 1 mM N6,2P-O-dibutyryladenosine-
3P :5P-cyclic monophosphate (Bt2cAMP) in serum-
free DMEM for 3 h [15]. K-Thrombin or thrombin
mutants were added to the cells, then 3 h later the
cells were observed by phase-contrast microscopy or
subjected to immunocytochemistry. In the competi-
tion experiments, astrocytes were plated and cultured
as above. After pretreatment with 1 mM Bt2cAMP,
increasing concentrations (up to 13.8 nM) of
S205A mutant were added to the cells and incubated
for 30 min. K-Thrombin (2.8 pM) was then added
to the cells and after 3 h cells were observed by
phase contrast microscopy and counted to score
di¡erentiated vs. undi¡erentiated cells; for each sam-
ple, at least three wells and 200 cells/well were
counted.
2.8. Immunocytochemistry
Cells were grown on coverslips and after thrombin
stimulation cultures were ¢xed by a 20-min exposure
to cold 3.7% formaldehyde in PBS, permeabilized
with 0.1% Triton X-100 in PBS for 5 min and then
processed for immunocytochemistry. The coverslips
were incubated for 20 min at room temperature
with a monoclonal antibody directed against GFAP
(Sigma Immuno-Chemicals, FRG) at a 1:400 dilu-
tion in a PBS^0.2% gelatin solution, washed with
the same solution and ¢nally incubated for 20 min
at room temperature with a £uorochrome-conjugated
secondary antibody. An anti-mouse IgG (Fc-speci¢c)
£uorescein-isothiocyanate (FITC)-conjugated (Sigma
Immuno-Chemicals, FRG) was used as secondary
antibody, at a 1:600 dilution in PBS^0.2% gelatin;
coverslips were washed several times, mounted with
Mowiol (Hoechst, FRG) on microscope slides and
cells were analyzed by a Zeiss Axiovert 10 photomi-
croscope using a 63U Plan-Apochromat lens and
£uorescein ¢lters (450^490, FT510-LP520).
2.9. RT-PCR analysis of thrombin receptors
One Wg of cell or tissue RNA was dissolved in 10 Wl
nuclease-free water, heated for 10 min at 70‡C and
cooled on ice. The reverse transcription was per-
formed in a ¢nal volume of 20 Wl containing 50 mM
Tris-HCl pH 8.3, 40 mM KCl, 6 mM MgCl2, 10 mM
DTT, 500 WM dNTPs, 10 pmol of a mixture of hexa-
random primers, 40 U RNasin and 20 U Moloney-
MLV reverse transcriptase. After 1 h at 42‡C, en-
zyme was inactivated at 95‡ and the reaction mixture
was diluted to 100 Wl with sterile water. Two Wl of
the reverse transcribed mixture were used for the
PCR reaction. The PCR mixture contained 10 mM
Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl2,
0.001% gelatin, 100 WM dNTP, 20 pmol of each
primer and 1.25 U of AmpliTaq-Gold up to a ¢nal
volume of 50 Wl. AmpliTaq-Gold enzyme was acti-
vated for 10 min at 95‡C in a thermalcycler (Bio-
metra Trio-Thermoblock) before starting the ampli-
¢cation cycles. Ampli¢cation was carried for 40
cycles of 60 s denaturation at 94‡C, 60 s annealing
at 52‡C, and 90 s of extension at 72‡C. In the last
cycle, the extension step was prolonged for 5 min
and temperature was then decreased to 4‡C. For
L-actin ampli¢cation the oligonucleotides described
by Khiri et al. [33] were used leading to the ampli¢-
cation of a 493-bp L-actin DNA fragment. For PAR-
1 and PAR-3 ampli¢cation two pairs of oligonucleo-
tides were designed, in DNA regions highly con-
served between rat and mouse. The sense primer,
5P-CATCACCACCTGCCACG-3P (PAR-*5P), was
common for PAR-1 and PAR-3. The antisense prim-
ers were 5P-TCAACGGATCGATGCAGC-3P for
PAR-1 and 5P-TGCCATTGCCGACTAAGG-3P for
PAR-3; when used with PAR-*5P in the ampli¢ca-
tion reaction, they gave a fragment of 358 and
402 bp, respectively.
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3. Results
3.1. Production, puri¢cation and ecarin activation of
s-prethrombin-2 mutants
A cDNA coding for s-prethrombin-2, a secreted
form of human prethrombin-2 [18], was used as a
template to introduce single amino acid substitutions
in the B-chain of thrombin. Five mutations, H43N,
D99N, G203A, S205A and S205T (thrombin B-chain
numbering) were targeted to the catalytic site,
namely residues in the catalytic triad H43, D99 and
S205, and to the adjacent G203, which is an essential
residue for the con¢guration of the oxy-anion bind-
ing site of thrombin. S205A substitution has previ-
ously been described for bovine and human pro-
thrombin [8,9,14] and reported to result in a
catalytically inactive thrombin. This mutant was
used as a negative control in the functional assays.
A further substitution replaced the basic amino acid
R73 with the acidic residue glutamic acid (E). R73 is
located in a surface domain, the anion-binding exo-
site-1 region, which is the proposed ¢brinogen recog-
nition site and also the site of interaction with recep-
tor, thrombomodulin as well as with hirudin [34].
To obtain the prethrombin-2 mutants, the cDNA
coding for the human s-prethrombin-2 was subjected
to site-speci¢c mutagenesis, as described in Section 2.
To produce large amounts of recombinant pre-
thrombin-2 mutants, stable transfection experiments
were performed in DXB11 cells. Several dhfr stable
transformants were obtained for each mutant vector;
all clones were selected through exposure to increas-
ing amounts of MTX, up to 40 nM. Clones that
showed higher levels of protein secretion were grown
at a larger scale for further characterization [18]. The
concentration of the recombinant prethrombin-2 mu-
tants in the culture medium was measured by ELISA
and varied from 8^10 Wg/ml of culture medium for
S205A and S205T, 1^2 Wg/ml of culture medium for
R73E, G203A, D99N, to 0.5 Wg/ml of culture me-
dium for H43N.
Recombinant s-prethrombin-2 mutants were puri-
¢ed to apparent homogeneity from serum-free media
through two passages on a heparin^Sepharose col-
umn. After the ¢rst chromatographic step, samples
were activated in vitro by ecarin from E. carinatus
venom. An additional puri¢cation step on a heparin^
sepharose column was performed to eliminate ecarin
from activated samples. Under our chromatographic
conditions, ecarin did not bind to heparin^sepharose
and was eluted with the £ow-through fraction from
the column. In fact, the £ow-through material was
able to activate puri¢ed human prothrombin to en-
zymatically active thrombin after incubation at 37‡C
for 1 h (results not shown).
3.2. Amidolytic and clotting activity of K-thrombin
mutants
We have already reported that the r-thrombin ob-
tained by ecarin activation of s-prethrombin-2,
shows the same esterolytic and coagulant activity as
K-thrombin [18]. Fig. 1 and Table 1 summarize the
results obtained when the enzymatic activity of
thrombin mutants, after activation with ecarin, was
assessed using a chromogenic substrate (S-2238) as
Fig. 1. Amidolytic activity of thrombin mutants. The amidolytic
activity of thrombin mutants was determined by a chromogenic
substrate assay using the synthetic peptide S-2238 as a sub-
strate. The amidolytic activity was determined by monitoring
the absorbance at 405 nm at 2-min intervals for 20 min. (A)
2 nM recombinant protein. (B) 0.5 WM recombinant protein.
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well as the macromolecular substrate ¢brinogen. The
anion-binding surface mutant R73E had the same
amidolytic activity as the r-thrombin (Fig. 1A).
Among the active site mutants, H43N, D99N, and
S205T showed a dramatically reduced enzymatic ac-
tivity, which was totally undetectable with the S205A
mutant as well as with the G203A mutant (Fig. 1B).
We also evaluated the catalytic e⁄ciency of the
thrombin mutants. As shown in Table 1, the Km
and kcat of R73E toward the chromogenic substrate
S-2238 are in good agreement with the Km and kcat of
K-thrombin and of r-thrombin with the same sub-
strate. S205T, on the contrary, showed a very low
catalytic e⁄ciency (kcat = 0.035 s31), although the
Km value was comparable to the Km value of K-
thrombin. The coagulant activity of mutants
S205A, G203A, S205T, D99N, H43N correlated
with the amidolytic activity, while the coagulant ac-
tivity of the R73E mutant was 85^90% lower, which
suggests that R73 plays a role in ¢brinogen recogni-
tion.
3.3. Mitogenic activity of K-thrombin mutants
The mitogenic e¡ects of thrombin mutants and r-
thrombin were studied in a mouse ¢broblast cell line,
NIH3T3, and on a primary culture of rat cortical
type-1 astrocytes. Increasing concentrations of puri-
¢ed recombinant proteins were added to the culture
medium of serum-deprived growth-arrested cells.
DNA synthesis was measured by incorporation of
Fig. 2. Mitogenic activity of recombinant thrombin mutants.
[3H]thymidine incorporation in mouse ¢broblast NIH3T3 cells
(A) and primary cultures of rat cortical type-1 astrocytes (B).
Serum-deprived, growth-arrested cells were exposed to increas-
ing concentrations of puri¢ed r-thrombin mutants. DNA syn-
thesis was evaluated by measuring the [3H]thymidine incorpora-
tion, as described in Section 2. The results are the mean of
three independent experiments and are expressed as a percent
of basal value.
Table 1
Amidolytic and coagulant activity of recombinant thrombin mutants
Sample S-2238 hydrolysis Fibrinogen clotting assay
(% of K-thrombin)
kcat (s31) Km (WM) kcat/Km (Wmol31 s31 kcat/Km (% of K-thrombin)
K-Thr 38.89 þ 1.92 2.93 þ 0.21 13.25 þ 0.78 100 þ 5.2 100 þ 2.8
r-Thr 35.41 þ 2.43 2.57 þ 0.24 13.76 þ 0.98 103 þ 7.2 98 þ 3.4
R73E 34.67 þ 1.83 1.98 þ 0.21 17.51 þ 1.21 132 þ 9.1 15.4 þ 2.8
S205T 0.035 þ 0.0048 2.15 þ 0.19 0.0161 þ 0.0016 0.121 þ 0.012 0.15 þ 0.08
D99N 0.0028 þ 0.00042 1.96 þ 0.21 0.0014 þ 0.0002 0.01 þ 0.0015 n.d.
H43N 0.0019 þ 0.00034 2.05 þ 0.19 0.0009 þ 0.0002 0.007 þ 0.0015 n.d.
S205A n.d. n.d. n.d. n.d. n.d.
G203A n.d. n.d. n.d. n.d. n.d.
Amidolytic activity of thrombin mutants was determined by a chromogenic peptide substrate (S-2238) assay. Values were calculated
by linear regression analysis of data. Fibrinogen clotting activity was determined as described in Section 2 and samples were tested in
triplicate. The results represent the means þ S.D. of three independent experiments. n.d., not detected.
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[3H]thymidine. The e¡ect of r-thrombin and mutants
on DNA synthesis is shown in Fig. 2A (NIH3T3)
and Fig. 2B (rat astrocytes). r-thrombin strongly in-
creased the [3H]thymidine incorporation, in a dose-
dependent manner, and in a range of concentrations
from 0.1 to 10 nM with a maximum e¡ect at 10 nM
in both cell cultures. Also in these assays, plasma-
derived K-thrombin and r-thrombin behaved identi-
cally (results not shown). The enzymatically active
mutant R73E also promoted cell division in a dose-
dependent manner, paralleling r-thrombin e¡ects.
The catalytic site mutants with a reduced enzy-
Fig. 3. E¡ect of r-thrombin and mutants thereof on Bt2cAMP-induced morphological di¡erentiation of rat cortical astrocytes. Puri¢ed
astrocytes were prepared as described in Section 2, and cell were photographed under the phase-contrast microscope. (A) Cells cul-
tured in DMEM supplemented with 10% FCS. (B) Cells di¡erentiated to a stellate morphology by treatment with 1 mM Bt2cAMP in
DMEM containing 0.1% BSA for 3 h. (C) Bt2cAMP-di¡erentiated cells treated with 10 pM r-thrombin. (D) Bt2cAMP-di¡erentiated
cells treated with 10 pM R73E. (E) Bt2cAMP-di¡erentiated cells treated with 250 pM D99N. (F) Bt2cAMP-di¡erentiated cells treated
with 250 pM S205T. (G) Bt2cAMP-di¡erentiated cells treated with 250 pM G203A. (H) Bt2cAMP-di¡erentiated cells treated with 250
pM S205A. Magni¢cation, 256U.
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matic activity, H43N, D99N, and S205T, also in-
duced cell proliferation, although at a higher protein
concentration, with a dose-dependent activity in a
concentration range of 10^100 nM, and maximal in-
duction at 100 nM. The G203A mutant, which did
not show any enzymatic activity in either the amido-
lytic assay or the ¢brinogen clotting assay, did not
induce cell proliferation, thus behaving like the inac-
tive mutant S205A.
3.4. Reversion of astrocyte stellation
Besides being a mitogen for astrocytes, thrombin is
also involved in the regulation of maintenance of
stellate morphology. Primary cultures of rat cortical
type-1 astrocytes have a £at and epithelial-like, un-
di¡erentiated morphology, when cells are cultured in
media containing 10% serum. However, when cells
are treated with agents that increase the intracellular
cyclic AMP concentration, they extend long proc-
esses resulting in a stellate morphology [15,16]. Using
this culture system, we investigated whether r-throm-
bin and its mutants could produce morphological
e¡ects in Bt2cAMP di¡erentiated rat cortical astro-
cytes. Fig. 3 shows the results of these experiments.
Rat cortical astrocytes cultured in 10% FCS had an
epithelial-like morphology (Fig. 3A). Treatment for
3 h with 1 mM Bt2cAMP induced a stellate morphol-
ogy in 98% of the cells (Fig. 3B). The addition of 10
pM r-thrombin to stellate cells completely reverted
astrocyte stellation (Fig. 3C) even though the
Bt2cAMP had not been removed from the medium.
The same concentration (10 pM) of the enzymati-
cally active mutant R73E also reverted the stellation
(Fig. 3D). Moreover, mutants with a very low ami-
dolytic activity, D99N and S205T (Fig. 3E,F), even
at a concentration of 250 pM, caused only a slight
spreading of the cell soma in about 10% of the cells.
Addition of the mutants without proteolytic activity
(G203A and S205A), at a concentration of 250 pM
did not revert stellation (Fig. 3G,H). Immunocyto-
chemical analysis was also carried out with an anti-
body against the astrocyte-speci¢c cytoskeletal pro-
tein GFAP [22]. Fig. 4 shows the results obtained by
GFAP indirect immuno£uorescence staining of cells.
The majority (s 98%) of cells expressed GFAP im-
munoreactivity (Fig. 4A), and, after the exposure to
Bt2cAMP under serum-free conditions, processes
could be seen emerging from the cell soma (Fig.
4B). Addition of r-thrombin (Fig. 4C) and R73E
(Fig. 4D), both at a concentration of 250 pM, pro-
duced a rapid reversion to the undi¡erentiated phe-
notype. After exposure to the proteins, many proc-
esses disappeared within 30 min and within 2 h the
reversion was complete. The active site mutants
D99N and S205T, at a concentration of 1.25 nM,
reverted astrocyte stellation in 5^10% of the cells
(Fig. 4E,F, respectively).
3.5. Receptor occupancy by the inactive S205A
mutant
Since the correlation between thrombin mutants
catalytic activity and their ability to promote cell
Fig. 4. E¡ect of r-thrombin and mutants thereof on the GFAP
expression pattern of rat cortical astrocytes. (A) Cells cultured
in DMEM supplemented with 10% FCS. (B) Stellate morphol-
ogy induced by treatment with 1 mM Bt2cAMP in DMEM
containing 0.1% BSA for 3 h. (C) Bt2cAMP-di¡erentiated cells
treated with 10 pM r-thrombin. (D) Bt2cAMP-di¡erentiated
cells treated with 10 pM R73E. (E) Bt2cAMP-di¡erentiated cells
treated with 1.25 nM D99N. (F) Bt2cAMP-di¡erentiated cells
treated with 1.25 nM S205T. Magni¢cation, 517U.
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growth in ¢broblasts and astrocytes, and reversion of
stellation in astrocytes we asked whether a proteo-
lytically activated receptor was involved. The S205A
mutant is devoid of enzyme activity, yet the domain
involved in receptor recognition is intact, thus recep-
tor occupancy by S205A mutant could prevent its
activation by thrombin and, ultimately, prevent as-
trocyte reversion. Fig. 5 shows the results of an ex-
periment where astrocytes were induced to di¡eren-
tiate by treatment with 1 mM Bt2cAMP and then
exposed to increasing concentrations of S205A. After
30 min, 2.8 pM r-thrombin was added to the cells.
As shown in Fig. 5, 2.8 pM r-thrombin would pro-
duce 65% reversion of astrocyte stellation. After ex-
posure to S205A mutant reversion of stellation was
inhibited in a dose-dependent mode. A concentration
of 13.8 nM S205A (ratio thrombin/S205A = 1/5000)
completely prevented the reversion of astrocytes
caused by 2.8 pM thrombin.
3.6. Receptor expression
Data illustrated above pointed to a role for a pro-
tease-activated receptor (PAR) mediating thrombin
e¡ects on ¢broblast and astrocyte proliferation and
on astrocyte reversion of morphological di¡erentia-
tion. The expression of PAR-1 has been demon-
strated in a variety of cells from di¡erent organisms
[35], including mouse ¢broblasts [36], while the ex-
pression of PAR-3 seems to be related to speci¢c
functions [37]. We checked the expression of PAR-1
and PAR-3 in NIH3T3 ¢broblasts and in rat primary
astrocytes by a semi-quantitative RT-PCR procedure
[33]. Fig. 6 shows the results of a RT-PCR analysis
of the expression of PAR-1 and PAR-3 utilizing for
each receptor a set of oligonucleotides spanning se-
quences which are conserved between mouse and rat.
Fig. 5. E¡ect of S205A thrombin mutant on the thrombin in-
duced reversion of stellation in rat astrocytes. (A) Undi¡erenti-
ated cells in astrocytes cultured in presence (FCS), or in ab-
sence (w/o FCS) of fetal calf serum, treated with 1 mM
Bt2cAMP for 3 h (Bt2cAMP), and exposed to 13.8 nM S205A
thrombin mutant. (B) Rat astrocytes were induced to stellate by
treatment with 1 mM Bt2cAMP for 3 h and then exposed to
the indicated concentrations of recombinant K-thrombin
(rThrombin). (C) Rat astrocytes induced to stellate with 1 mM
Bt2cAMP were exposed to increasing concentrations (up to 13.8
nM) of S205A mutant. Thirty minutes later, 2.8 pM r-thrombin
was added to the cells to achieve the indicated r-thrombin/
S205A ratio. In all the experiments, cells were observed by
phase contrast microscopy and counted to score undi¡erenti-
ated vs. di¡erentiated cells ; for each sample, at least three wells
and 200 cell/well were counted. The results are expressed as
mean, the error bar represents S.D.
C
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Mouse spleen, used as a control, has been shown to
express both PAR-1 and PAR-3, while in primary rat
astrocytes only PAR-1 was present.
4. Discussion
The multifunctional thrombin molecule mediates
hemostasis control, and elicits cellular responses in
various cell types [34]. It is involved in cell prolifer-
ation and in the modulation of morphological di¡er-
entiation of neurons and astrocytes [4,6]. Several
lines of evidence indicate that the thrombin-stimu-
lated mitogenic response and thrombin involvement
in morphological di¡erentiation require a catalyti-
cally active thrombin [3,4,11,12,15^17,38].
The cloning of a platelet thrombin receptor [10]
demonstrated the proteolytic cleavage mechanism
of its activation. Successively, platelet-type thrombin
receptors were cloned from cells responsive to throm-
bin-induced mitogenesis, i.e. hamster lung ¢broblasts
[39], and rat aortic smooth-muscle cells [40]. These
receptors belong to a class of G-protein-coupled re-
ceptors characterized by seven transmembrane re-
gions. They share a high degree of identity in the
amino acid sequence of the extracellular N-terminal
domain de¢ning the cleavage site, and in the recog-
nition domain of the amino terminus unmasked by
thrombin cleavage. These ¢ndings prompted specu-
lation that a proteolytic mechanism of receptor acti-
vation could also mediate thrombin-induced mito-
genic activity. However, con£icting results have
emerged from studies about proteolytic activation
of a receptor as a prerequisite for the thrombin-in-
duced mitogenic response in murine macrophages
and human monocytes [12] and for the chemotactic
response in human neutrophils and monocytes
[13,14]. In fact, in the case of chemotactic response
of neutrophils and monocytes, di¡erent authors
[13,14], by using a genetically engineered S205A
thrombin mutant, have convincingly demonstrated
that a proteolytic activation of a receptor is not re-
quired.
To gain further insight into the correlation be-
tween the thrombin enzymatic activity and the ability
to induce cell proliferation and to modulate astrocyte
stellation, we produced a panel of recombinant
thrombin mutants with altered proteolytic activity.
Single amino acid substitutions were introduced in
the catalytic triad (H43N, D99N, S205A and
S205T), in the oxy-anion binding site (G203A) and
in the anion binding exosite-1 region (R73E), which
is the proposed site of interaction with the ¢brinogen
and the thrombin receptor, among other macromo-
lecules.
The mutants were obtained by site-speci¢c muta-
genesis of the cDNA coding for a secreted form of
human prethrombin-2, which allowed the recombi-
nant protein to accumulate in the culture medium
of stable transformant DXB11 cells [18]. The
amounts of r-thrombin mutants produced using
this expression system ranged from 0.5 Wg/ml of cul-
ture medium for H43N to 8^10 Wg/ml of culture me-
dium for S205A or S205T, and for each mutant con-
venient amounts of protein could be prepared for
biochemical and functional studies.
The replacement of the catalytic serine-205 with
threonine had an unexpected e¡ect: the S205T
showed some enzymatic activity with the synthetic
peptide substrate S-2238, i.e. a Km (2.15 WM) com-
parable to the Km of K-thrombin toward the same
substrate, but a kcat 1000-fold lower (Fig. 1B and
Table 1). These results suggest that the replacement
of S205 with threonine does not prevent the enzyme
acylation step, but the subsequent deacylation is
much less e⁄cient. The S205T mutant had an im-
paired catalytic activity also toward the procoagulant
substrate ¢brinogen. Indeed, the ¢brinogenolytic ac-
tivity of S205T was 0.15% with respect to that ex-
erted by r-thrombin (Table 1). However, 100 nM
S205T induced cell proliferation (Fig. 2) and 1.25
Fig. 6. RT-PCR analysis of PAR-1 and PAR-3 expression in
NIH3T3 and rat astrocytes. The experimental conditions were
as described in Section 2.
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nM S205T reverted stellation in 10% of an astrocyte
population (Figs. 3 and 4).
The other catalytic site mutants, H43N and D99N,
exerted a very low amidolytic activity on the syn-
thetic peptide substrate (Fig. 1B and Table 1). This
result is in agreement with the role of H43 and D99
residues in the catalytic mechanism of serine pro-
teases where H43 behaves as a proton acceptor (do-
nated by the serine hydroxyl group) and its resulting
positive charge is stabilized by the negative charge of
D99. We did not detect any cleavage of ¢brinogen by
H43N or D99N mutants. Fisher et al. [41] described
a D419N mutant of human prothrombin (corre-
sponding to D99N in the thrombin numbering sys-
tem) that also lacked coagulant activity. Like S205T,
also H43N and D99N, at a concentration of 100 nM,
induced cell proliferation and, at 1.25 nM, reverted
stellation in about 10% of an astrocyte cell popula-
tion.
Substitution of G203 with alanine dramatically af-
fected thrombin activity. In fact, this mutant was
totally devoid of enzymatic activity suggesting that
G203 plays an essential conformational role (Fig. 1B
and 2 and Table 1).
The substitution of the net positive charge of R73
with the net negative charge of glutamic acid in the
anion binding exosite-1 did not interfere with throm-
bin proteolytic activity when the synthetic substrate
S-2238 was used (Fig. 1A). However, the ¢brinogen
clotting activity of the R73E mutant was only 15% of
that of r-thrombin (Table 1). These ¢ndings evoke
the R68E thrombin mutant, reported by Wu et al.
[42]. Indeed, R68E had an amidolytic activity similar
to that of plasma-derived thrombin, but its clotting
activity was 6 1% of that of thrombin. These results
suggest that each single charge on the anion binding
exosite-1 surface is involved in ¢brinogen recognition
or positioning for correct cleavage by the catalytic
site.
We used the above-described thrombin mutants to
investigate their ability to induce cell proliferation in
mouse NIH3T3 ¢broblasts, in rat cortical astrocytes,
and to revert astrocyte stellation. Mutants S205A
and G203A, which did not show any enzymatic ac-
tivity, did not stimulate cell proliferation in any cell
type or revert stellation of rat astrocytes (Figs. 2 and
3). H43N, D99N and S205T, which retained some
enzymatic activity, induced both cell proliferation
(Fig. 2) and partial reversion of astrocyte stellation
when used at a concentration 100-fold higher than K-
thrombin or the catalytically active R73E mutant
(Fig. 3). Interestingly, the induction of cell prolifer-
ation by S205T in rat cortical astrocytes (Fig. 2B)
showed a di¡erent kinetic than in ¢broblasts
(Fig. 2A).
These data show that enzymatic activity is re-
quired to stimulate proliferation of mouse ¢broblast
NIH3T3 cells and rat cortical astrocytes as well as to
revert astrocyte stellation, thus supporting the hy-
pothesis that proteolytic activation of a thrombin
receptor is required for the thrombin-induced mito-
genic response and astrocyte morphological di¡eren-
tiation. Evidence for this requirement comes also
from Trejo et al. [43], who demonstrated that a pro-
teolytically activated thrombin receptor is necessary
and su⁄cient for mitogenesis of mouse lung ¢bro-
blasts from receptor knockout mice.
Three di¡erent proteolytically activated thrombin
receptors have been characterized so far, namely
PAR-1, PAR-3 [10,37] and, more recently PAR-4
[44,45], sharing the same mechanism of activation
and, perhaps, di¡erent relevance for speci¢c throm-
bin functions in cell activation. The role of a PAR in
the reversion of astrocyte stellation was also demon-
strated by the experiments illustrated in Fig. 5. The
S205A mutant, fully devoid of enzymatic activity,
was able to prevent the reversion of astrocyte stella-
tion mediated by thrombin, by competing for recep-
tor occupancy. The rather high concentration of the
mutant protein (ratio thr/S205A = 1/5000) required to
fully prevent the thrombin e¡ect was expected in a
process where the receptor recognition by the intact
exosite 1 of the S205A mutant could not be followed
by the stabilizing interaction of the receptor molecule
with the active site serine, missing in the mutant.
PAR-1 and PAR-3 receptors are both expressed in
NIH3T3 ¢broblasts; in rat astrocytes, where the
presence of PAR-1 had been already demonstrated
[46], the RT-PCR analysis did not detect any expres-
sion of PAR-3.
Our studies, together with previous studies on a
R73A mutation [9], also suggest that residue R73 is
involved in ¢brinogen recognition. In fact, R73E had
the same enzymatic activity as r-thrombin, but a
much lower ¢brinogen clotting activity. However,
the R73E mutant retained unimpaired ability to in-
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duce cell proliferation and to revert astrocyte stella-
tion, thus indicating that R73 does not play a critical
role in thrombin^receptor interaction. These data
also add further evidence to the notion that, within
the large exosite 1, the binding sites for di¡erent
macromolecules are not identical, although they
may overlap [47].
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